Immunobiotherapy directed against mutated and aberrantly expressed gene products in pancreas cancer
- 15 April 2005
- journal article
- review article
- Published by Wiley in Journal of Cellular Biochemistry
- Vol. 94 (6) , 1069-1077
Abstract
Genetic alterations are responsible for the development of cancer in ductal cells of the pancreas. These genetic changes result in abnormal molecular expression of proteins that are involved in cell proliferation, cell cycle control and adhesion. Some of the genetic mutations result in aberrant proteins that can be recognized as novel or foreign by cells of innate and adaptive immune systems. These are appropriate targets for therapeutic intervention which may involve immunobiologic approaches. These approaches may be less effective because of immune escape mechanisms developed by tumor cells within the microenvironment of the tumor mass. Immunobiotherapy intervention of pancreas cancer must circumvent these obstacles and integrate effective immunotherapy with molecularly targeted approaches to pancreas cancer intervention.Keywords
This publication has 43 references indexed in Scilit:
- Frontline: Characterization of BT3 molecules belonging to the B7 family expressed on immune cellsEuropean Journal of Immunology, 2004
- Predictive Factors for Pancreatic Cancer in Patients with Chronic Pancreatitis in Association with K-rasGene MutationEndoscopy, 2004
- EGFR Mutations in Lung Cancer: Correlation with Clinical Response to Gefitinib TherapyScience, 2004
- Activating Mutations in the Epidermal Growth Factor Receptor Underlying Responsiveness of Non–Small-Cell Lung Cancer to GefitinibNew England Journal of Medicine, 2004
- Missense Mutations of MADH4 Clinical Cancer Research, 2004
- Focus on pancreas cancerCancer Cell, 2002
- Innate Immune RecognitionAnnual Review of Immunology, 2002
- Disruption of the antiproliferative TGF-β signaling pathways in human pancreatic cancer cellsOncogene, 1998
- Vaccination with mutant ras peptides and induction of T-cell responsiveness in pancreatic carcinoma patients carrying the corresponding RAS mutationThe Lancet, 1995
- MUC‐1 Epithelial Tumor Mucin‐Based Immunity and Cancer VaccinesImmunological Reviews, 1995